ArticleDiscover oncology2025
Effects of apigenin on the proliferation, migration, and apoptosis of human diffuse large B-cell lymphoma OCI-LY3 cells.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the effects of apigenin on the proliferation, migration, and apoptosis of human diffuse large B-cell lymphoma (DLBCL) OCI-LY3 cells.
methodsOCI-LY3 cells were cultured in vitro and treated with varying concentrations of apigenin (20, 40, 80 µmol/L). The CCK-8 assay, Transwell assay, and flow cytometry were employed to detect the proliferation, migration, invasion, and apoptotic abilities of each cell group, respectively. Western blot was employed to measure the expression levels of apoptosis-related proteins (Bax, Bcl-2, Caspase-3). BALB/c mice were used to establish xenograft tumor models via subcutaneous injection of OCI-LY3 cells. Mice were randomly divided into a vehicle group, an apigenin group (10 mg/kg), and a cyclophosphamide group (20 mg/kg) to evaluate the effects of apigenin on tumor growth in vivo. Additionally, Ki-67 expression (a marker for tumor proliferation) was assessed by immunohistochemistry in tumor tissues.
resultsCompared to the DMSO group, apigenin at 20, 40, and 80 µmol/L greatly reduced cell proliferation, migration, invasion, and Bcl-2 expression while increasing apoptosis rates and the abundance levels of Bax and cleaved Caspase-3. Apigenin also suppressed the growth of xenograft tumors and reduced Ki-67 expression in tumor tissues.
conclusionApigenin exerts anti-DLBCL effects both in vitro and in vivo, offering a novel therapeutic strategy for lymphoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.